Improvement of Subjective Well-being and Enduring Symptomatic Remission, A 5-Year Follow-up of First Episode Schizophrenia

Abstract

Early improvement of subjective well-being is related to ESR in first episode schizophrenia or related disorders.

A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents

“…61,62 Research indicates that subjective well-being or quality of life is improved more by atypical antipsychotic agents than by conventional antipsychotic agents, they can also influence treatment adherence, and atypical agents improve the likelihood of patients achieving remission. 63,64 Collectively, these data strongly suggest that assessing a patient's perspective of antipsychotic treatment can exert clinical advantages because this perspective may be associated with increased adherence and thus improvements in long-term prognosis and outcomes.…”

Reasons and Outcomes of Olanzapine Dose Adjustments in the Outpatient Treatment of Schizophrenia

“…Large-scale observational studies could provide insight into factors related to antipsychotic drug dose adjustments, and how dose changes impact on eff ectiveness and tolerability in day to day clinical practice. These data may result in a better understanding of the complex nature of response to an antipsychotic treatment [13,20] . The results presented in this paper were obtained from the European Schizophrenia Outpatient Health Outcomes (SOHO) study, a 3-year prospective observational study of the treatment of schizophrenia in the outpatient setting [15] .…”

Drug Attitude in Adolescents

“…34Y36 Moreover, SE has been found to be positively associated with treatment outcome and symptomatic remission. 15,37,38 Several studies have highlighted the fundamental role played by SE, in particular attitude toward APs, in determining compliance with treatment. 39 These include a recent paper by Gaebel et al 14 who, among a series of outcome parameters, found SE, evaluated with DAI, to be the best predictor of efficacy (fewer treatment discontinuations).…”